IKT (Inhibikase Therapeutics) Tariff Resilience Score: 5/10 (As of Jul. 06, 2026)


IKT Inhibikase Therapeutics Inc IKT
28 GF Score
Price $1.98
! 1 Warning Sign
View Full Analysis

What is Inhibikase Therapeutics Tariff Resilience Score?

Inhibikase Therapeutics IKT -0.50% 28 Tariff Resilience Score is 5 as of Jul. 06, 2026. GuruFocus rates IKT with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,369 Biotechnology companies, Inhibikase Therapeutics ranks better than 62.38% on this metric.

Inhibikase Therapeutics has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Inhibikase Therapeutics has Inhibikase Therapeutics is moderately vulnerable to tariffs due to its reliance on international suppliers for drug development. While it can seek alternative suppliers, the specialized nature of its products limits flexibility.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Inhibikase Therapeutics might have Average Resilient.

Inhibikase Therapeutics  (NAS:IKT) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Inhibikase Therapeutics Tariff Resilience Score Related Terms

IKT vs FHTX, OBIO, FULC: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Inhibikase Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inhibikase Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Inhibikase Therapeutics's Tariff Resilience Score falls into.


IKT
28GF Score
Inhibikase Therapeutics Inc IKT
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Inhibikase Therapeutics (IKT) has a Tariff Resilience Score of 5 as of Jul. 06, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Inhibikase Therapeutics ranks #515 out of 1369 companies in the Biotechnology industry, placing it in the top 37.6%.
Is Inhibikase Therapeutics' Tariff Resilience Score too high?
Inhibikase Therapeutics' current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Inhibikase Therapeutics' value of 5 is 25% above this industry median. Based on the distribution chart, Inhibikase Therapeutics ranks #515 out of 1369 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Inhibikase Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Inhibikase Therapeutics' Tariff Resilience Score compare to FHTX and OBIO?
According to the Biotechnology industry distribution chart, Inhibikase Therapeutics ranks #515 out of 1369 companies for Tariff Resilience Score. This puts Inhibikase Therapeutics in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Inhibikase Therapeutics' value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,369 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inhibikase Therapeutics's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inhibikase Therapeutics's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibikase Therapeutics stock overvalued right now?
Inhibikase Therapeutics (IKT) has a current Tariff Resilience Score of 5. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Inhibikase Therapeutics' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Inhibikase Therapeutics (IKT), the current Tariff Resilience Score is 5 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inhibikase Therapeutics Business Description

Address 1000 N. West Street, Suite 1200, Wilmington, DE, USA, 19801
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
28GF Score

Get the complete analysis for IKT

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.98
Price